Internal Medicine · Los Angeles, CA
NPI
1700032497
Since 2008
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
711 W College St, Suite 203
Los Angeles, CA, 90012
Phone (213) 830-8960
Groups this clinician bills Medicare through
Medicare paid, 2024
$397K
4,999 services
Medicare patients, 2024
284
Average age 71
Drug cost, 2024
$2.2M
3,486 prescriptions
Company payments, 2025
$23K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel Brelian was code 99232 (hospital e&m - subsequent), 2,941 times for 95 patients. In total Daniel Brelian billed 4,999 services in 19 codes, and Medicare paid $397K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-03-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 2,941 | 95 | $64.80 | $191K |
| 99233 Hospital E&M - Subsequent | Facility | 1,507 | 93 | $97.58 | $147K |
| 99214 Office E&M - Established | Office | 191 | 133 | $98.95 | $19K |
| 99204 Office E&M - New | Office | 78 | 78 | $120.55 | $9,403 |
| 99223 Hospital E&M - Initial | Facility | 72 | 72 | $142.54 | $10K |
| 45380 Lower GI Endoscopy - Other | Facility | 69 | 68 | $137.45 | $9,484 |
| 43239 Upper GI Endoscopy | Facility | 60 | 58 | $66.56 | $3,994 |
| 91200 Standard X-ray | Office | 33 | 33 | $21.69 | $716 |
| 45385 Colonoscopy - Lesion Removal | Facility | 11 | 11 | $213.67 | $2,350 |
By year: 2022 $217K for 2,820 services; 2023 $324K for 4,096 services; 2024 $397K for 4,999 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel Brelian prescribed most often to Medicare patients was Famotidine, with 964 prescriptions and refills. In total Daniel Brelian wrote 3,486 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Famotidine Generic | 964 | 2,641 | 394 | $12K |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 336 | 336 | 320 | $4,984 |
| Pantoprazole Sodium Generic | 256 | 526 | 169 | $2,543 |
| Linzess Linaclotide | 247 | 510 | 96 | $262K |
| Xifaxan Rifaximin | 191 | 202 | 38 | $628K |
| Creon Lipase/Protease/Amylase | 155 | 171 | 55 | $462K |
| Lactulose Generic | 142 | 232 | 42 | $4,840 |
| Dicyclomine Hcl Generic | 120 | 223 | 39 | $1,987 |
| Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl | 118 | 118 | 116 | $1,878 |
| Ondansetron Odt Ondansetron | 86 | 86 | 19 | $2,840 |
| Sucralfate Generic | 85 | 149 | 60 | $6,835 |
| Rezdiffra Resmetirom | 81 | 81 | 30 | $316K |
| Dexlansoprazole Dr Dexlansoprazole | 47 | 102 | 17 | $16K |
| Ursodiol Generic | 47 | 137 | 17 | $15K |
| Mesalamine Er Mesalamine | 46 | 106 | 15 | $17K |
Brand drugs: 890 claims; generic drugs: 2,596 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel Brelian $23K ($23K in general payments such as food, travel and fees) from 12 companies. The largest payer was Madrigal Pharmaceuticals with $16K.
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals MDGL | 36 | $16K |
| Abbvie Inc. ABBV | 22 | $5,860 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 19 | $394 |
| Gilead Sciences, Inc. GILD | 16 | $283 |
| Janssen Biotech, Inc. JNJ | 8 | $204 |
| Pfizer Inc. PFE | 11 | $172 |
| Aimmune Therapeutics, Inc. | 3 | $83.64 |
| Phathom Pharmaceuticals, Inc. PHAT | 3 | $70.17 |
| Braintree Laboratories, Inc. | 2 | $39.58 |
| RedHill Biopharma Inc. RDHL | 1 | $33.25 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.